TB-500

What it is

The parent protein, thymosin beta-4, occurs naturally throughout the body and helps regulate actin, one of the proteins cells rely on to crawl toward an injury site and to reorganize their internal structure during repair. TB-500 keeps just the actin-binding segment of that larger protein, a change that researchers report makes it more stable while keeping the actin-related activity researchers are interested in.

Because it was developed first for use in horses, much of the earliest published interest in TB-500 sits in veterinary and animal work, not medicine tested in people. It has since drawn interest in a wider set of laboratory and small clinical studies exploring tissue repair, new blood vessel formation, and eye-surface healing, though it remains an unapproved research compound rather than a licensed medicine in any of those areas.

How it is studied

Research on TB-500 spans mouse models of muscle disease, a small human pilot study in patients recovering from a heart attack, and a randomized human trial of an eye-drop formulation for dry eye. The mouse work has generally measured muscle-tissue structure directly, while the human studies have relied on functional measures, such as heart-pumping efficiency after a heart attack or patient-reported eye symptoms, making the human evidence base considerably smaller and more preliminary than the animal-model literature.

What studies report

• A small pilot study in patients recovering from a heart attack reported that pre-treating transplanted cells with the parent protein's active fragment was linked to more than a 50 percent improvement in a measure of heart-pumping function compared with a control group. [1]
• In mice bred to lack a muscle-structural protein, the actin-binding fragment was linked to improved regeneration of skeletal muscle fibers over six months, a model researchers use to study muscular dystrophy. [2]
• A randomized trial of an eye-drop formulation containing this fragment reported that dry eye rated moderate to severe grew meaningfully milder, both in what a doctor could observe and what the patient felt, with effects that persisted after the treatment period ended. [3]

What is not known

The human evidence for TB-500 outside of the eye-drop trial rests on very small, early-stage studies rather than large randomized trials, and the fragment has not been directly compared against standard treatments in the tissue-repair contexts most often discussed in the research community. Because it originated as a veterinary compound, most of what is understood about how it behaves systemically in the body, how consistently it is cleared, and what happens with repeated use over months or years comes from animal research rather than a settled human record.

Regulatory status

TB-500 is not approved as a drug in the United States or elsewhere. Athletes competing under anti-doping rules are barred from using it, since the World Anti-Doping Agency includes it on its list of prohibited substances.